ALT
Companies
NASDAQ
Altimmune, Inc.
Health Care
$7.00
-$0.21 (-2.91%)
Price Chart
Overview
About ALT
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
Market Cap
$457.7M
Volume
15.5M
Avg. Volume
20.6M
P/E Ratio
-2.7619047
Dividend Yield
0.00%
Employees
64.0
Company Information
Latest News for ALT
Altimmune's Mid-Stage Pemvidutide Study Cleared By FDA For Obesity
January 31, 2022
Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance
May 7, 2024
Final Trade: WST, BTC, GLD, ALT
February 14, 2025
How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86%
May 9, 2025
Risk & Correlation Analysis
Market Correlation
0.76
Moderate Correlation
Volatility
High (0.84)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
High Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
High Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, ALT shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$457.7M
Volume15.5M
P/E Ratio-2.76
Dividend Yield0.00%
Important Dates
Next Dividend
September 14, 2018Next Earnings
February 27, 2025Related Securities
Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025